793 results about "Radionuclide" patented technology

The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and / or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and / or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and / or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and / or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and / or diagnostic agents.

Methods regarding local regional treatment in situ for an individual, such as of a tumor, are provided herein. A hydrogel composition is generated in situ in the tumor by administering a polymer, such as a polysaccharide or a polyamino acid, with a therapeutic agent, such as a radionuclide or a drug, and administering a cross-linking agent. The hydrogel / therapeutic agent composition is retained in the tumor for safe and efficient tumor therapy. Alternatively, a hydrogel composition is generated in situ in an artery which nourishes a tumor to occlude the artery.

The invention discloses a method for treating radioactive wastewater. The method for treating the radioactive wastewater comprises the steps of firstly carrying out reverse osmosis treatment on the radioactive wastewater, then enabling the radioactive wastewater to enter a continuous electrodeionization unit to be treated, and further removing radionuclide so as to enable treated wastewater to reach discharge requirements; and respectively filling different mixed ion exchange resin in a plain water chamber and a thick water chamber in a continuous electrodeionization membrane stack of the continuous electrodeionization unit, wherein mixed ion exchange resin filled in the plain water chamber comprises, by volume ratio, 30%-60% of strong-acid cation exchange resin, 40%-60% of strong-base anion exchange resin, and 0%-30% of weak-base anion exchange resin, mixed ion exchange resin filled in the thick water chamber comprises, by volume ratio, 20%-50% of strong-acid cation exchange resin, and the balance strong-base anion exchange resin. A weak dissociation polymer portion is used for improving selectivity of continuous electrodeionization membrane stack to trace amount radionuclide, radionuclide with extremely concentration can be effectively removed, and the method for treating the radioactive wastewater ensures that the final discharged water satisfies the discharge requirements.

Core-excited nanoparticle thermotherapy (CENT) represents a new paradigm in thermotherapy. The CENT method employs core-shell nanoparticles. The core of the nanoparticles is formed from one or more core-exciting, energy absorbing materials which absorbs core-exciting energy, either from an external energy source or from an energy source within the nanoparticle core (e.g., one or more radionuclides which undergo decay). Upon excitation by the core-exciting energy, the one or more core-exciting, energy absorbing materials reemit energy. A shell surrounds the particle nanoparticle core. The energy reemitted by the one or more core-exciting, energy absorbing materials is absorbed by the nanoparticle shell, so as to heat the shell of the nanoparticle. The heated nanoparticle then heats the surrounding region, to a temperature sufficient to detect, affect, damage or destroy the targeted cell or material. These core-shell nanoparticles can be administered to a patient in need thereof to treat diseases or disorders, including cancer. CENT nanoparticles can be optionally be bound to targeting agents that deliver them to the region of the diseased cell.